Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2.
Journal of medical economics（2023）
摘要
Ribociclib is both cost-saving and cost-effective compared with palbociclib for the 1L treatment of postmenopausal women with HR+/HER2- ABC in the UK.
更多查看译文
关键词
CDK 4/6 inhibitors,HR+/HER2− advanced breast cancer,I,I00,I1,I10,Ribociclib,breast cancer,cost-effectiveness,palbociclib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要